Dr. Feldman, the Taubman Institute collaborated in the creation of the now-established Center for RNA Biomedicine at the University of Michigan. It promotes and develops promotes and develops cross-disciplinary collaborations on RNA research across campus. NeuroNetwork for Emerging Therapies Feldman’s scientific (basic science) laboratory was initially established in 1988 and was later named the Program for Neurology Research and Discovery. In the proceeding 20 years, her lab grew to over 30 scientists and was renamed The NeuroNetwork for Emerging Therapies (www.mneuronet.org) in 2020. The mission of Feldman's research remains the same: to advance scientific discovery and establish therapies for neurological diseases. ALS Center of Excellence at Michigan Medicine After initially taking over the ALS Clinic at Michigan Medicine, now the Pranger ALS Clinic, Feldman combined ALS patient care and ALS clinical and scientific research. The newly formed ALS Center of Excellence at Michigan Medicine was certified by the ALS Association. Patient care and clinical trials happen through Pranger ALS Clinic, while basic science research is conducted through the NeuroNetwork. All ALS-related activities at the separate entities are merged under the ALS Center of Excellence to build a true bench to bedside framework, now directed by Feldman, with Dr. Stephen Goutman, Director of the Pranger ALS Clinic, serving as the associate director. Mentorship Feldman sees some of her greatest accomplishments as guiding and supporting the future of medical science through mentoring and inspiring the next generation of scientists and physicians. Nine scientists have received their Ph.D. degrees under her tutelage, and she has trained more than 100 postdoctoral fellows and neurologists to specialize in the understanding and treatment of neurological diseases. Research Amyotrophic Lateral Schlerosis (ALS) Feldman is renowned for her groundbreaking research in amyotrophic lateral sclerosis (ALS), an invariably fatal nerve affliction more commonly known as Lou Gehrig’s disease. In fact, her work developing a stem cell therapy for ALS has resulted in the first FDA-approved human clinical trial for a stem cell treatment for this condition. The Phase 1 and 2 trials supported the safety and feasibility of transplanting up to 16 million stem cells into the spinal cord of ALS subjects. This is just one of the many influential advances that have emanated from her laboratory. She has made national headlines for work uncovering links between ALS risk and pesticide exposures, and she and her team received a method-of-use patent in 2018 to repurpose a family of drugs,